Sugi Predict

Sugi Predict / Compounds / SCHEMBL203405

SCHEMBL203405

SCHEMBL203405

Nc1nccc2cc(Br)ccc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ROCK1 Q13464 9/20 0.58
▸ PLAU P00749 3/20 0.56
▸ F12 P00748 2/20 0.53
▸ BACE1 P56817 2/20 0.53
▸ NCF1 P14598 1/20 0.53
▸ NOS3 P29474 1/20 0.53
▸ NOS1 P29475 1/20 0.53
▸ NOS2 P35228 1/20 0.53
▸ MAP4K4 O95819 1/20 0.50
▸ PLG P00747 2/20 0.47
▸ F11 P03951 1/20 0.47
▸ KLKB1 P03952 1/20 0.47
▸ PRSS1 P07477 1/20 0.47
▸ PRSS2 P07478 1/20 0.47
▸ PRSS3 P35030 1/20 0.47
▸ PDPK1 O15530 1/20 0.44
▸ JAK2 O60674 1/20 0.44
▸ PLAT P00750 1/20 0.44
▸ ROCK2 O75116 1/20 0.43
▸ KCNH2 Q12809 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29627982 1.00 ROCK1 (0.58) ROCK1PLAUF12BACE1NCF1
SCHEMBL1839938 0.84 PLAU (0.56) ROCK1PLAUF12BACE1NCF1
SCHEMBL29439792 0.84 PLAU (0.56) ROCK1PLAUF12BACE1NCF1
SCHEMBL29824354 0.79 ROCK1 (0.61) ROCK1PLAUF12BACE1NCF1
SCHEMBL3856487 0.79 ROCK1 (0.61) ROCK1PLAUF12BACE1NCF1
SCHEMBL28216043 0.79 PLAU (0.54) ROCK1PLAUBACE1NOS1PLG
SCHEMBL24493042 0.76 ROCK1 (0.58) ROCK1PLAUF12BACE1NCF1
SCHEMBL17152703 0.76 ROCK1 (0.58) ROCK1PLAUF12BACE1NCF1
SCHEMBL582273 0.76 PLAU (0.56) PLAUPLGPLATKDM4EMEN1
SCHEMBL1536295 0.76 PLAU (0.51) ROCK1PLAUMAP4K4PLGPLAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092053-A1 KHK INHIBITORS GILEAD SCIENCES INC (US) 2026-04-02 — — US disclosed
EP-4681774-A2 KHK INHIBITORS Gilead Sciences, Inc. (US) 2026-01-21 — — EP disclosed
EP-4313967-B1 KHK INHIBITORS GILEAD SCIENCES INC (US) 2025-11-12 — — EP disclosed
US-12410160-B2 KHK inhibitors GILEAD SCIENCES, INC. (US) 2025-09-09 — — US disclosed
US-20250257035-A1 1,4-Substituted Piperidine Derivatives CEPHALON LLC 2025-08-14 — — US disclosed
US-12336991-B2 Factor XIIA inhibitors UNIVERSITY OF LEEDS (GB) 2025-06-24 — — US disclosed
US-20250136592-A1 C-LINKED INHIBITORS OF ENL/AF9 YEATS BRIDGE MEDICINES 2025-05-01 — — US disclosed
CN-115427035-B ENL/AF9 YEATS inhibitors 洛克菲勒大学 2025-04-22 — — CN disclosed
US-20240327412-A1 FACTOR XIIA INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2024-10-03 — — US disclosed
US-12098130-B2 1,4-substituted piperidine derivatives 89BIO LTD (IL) 2024-09-24 — — US disclosed
US-6797710-B2 CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY AKZO NOBEL N.V. (NL) 2004-09-28 — — US disclosed
US-20030199511-A1 Kinase inhibitors ABBVIE INC. 2003-10-23 — — US disclosed
US-20030187026-A1 Kinase inhibitors ABBOTT LABORATORIES 2003-10-02 — — US disclosed
US-20030130270-A1 Heterocyclic derivatives and their use as antithrombotic agents MERCK SHARP & DOHME B.V. (NL) 2003-07-10 — — US disclosed
WO-2003051366-A2 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER ABBOTT LABORATORIES (US) 2003-06-26 — — WO disclosed
US-6444672-B1 ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR AKZO NOBEL N.V. (NL) 2002-09-03 — — US disclosed
US-6432955-B1 ANTICOAGULANTS AKZO NOBEL N.V. (NL) 2002-08-13 — — US disclosed
US-6194409-B1 SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH AKZO NOBEL N.V. (NL) 2001-02-27 — — US disclosed
EP-0975600-A1 HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS Akzo Nobel N.V. (NL) 2000-02-02 — — EP disclosed
WO-1998047876-A1 HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS AKZO NOBEL N.V. (NL) 1998-10-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250257035-A1 1,4-Substituted Piperidine Derivatives FASN, CES1, CPT1A ROCK1 2370/4885PLAU 3784/4885F12 3922/4885
US-20030187026-A1 Kinase inhibitors MAP3K20, MAP3K19, MAP3K1 ROCK1 446/4885PLAU 2083/4885F12 2195/4885
US-20030199511-A1 Kinase inhibitors MAP3K20, MAP3K19, MAP3K1 ROCK1 446/4885PLAU 2083/4885F12 2195/4885
US-20240327412-A1 FACTOR XIIA INHIBITORS F11, F13B, F12 ROCK1 1243/4885PLAU 19/4885F12 3/4885
US-20260092053-A1 KHK INHIBITORS KHK, SLC5A2, HK1 ROCK1 620/4885PLAU 2314/4885F12 1746/4885
US-12410160-B2 KHK inhibitors KHK, KHDRBS1, NADK ROCK1 1150/4885PLAU 3447/4885F12 4118/4885
US-12098130-B2 1,4-substituted piperidine derivatives FASN, CES1, CPT1A ROCK1 2370/4885PLAU 3784/4885F12 3922/4885
US-12336991-B2 Factor XIIA inhibitors F11, F13B, F12 ROCK1 411/4885PLAU 34/4885F12 3/4885
US-20250136592-A1 C-LINKED INHIBITORS OF ENL/AF9 YEATS MLLT3, MLLT1, YEATS2 ROCK1 4077/4885PLAU 3931/4885F12 2159/4885
US-20030130270-A1 Heterocyclic derivatives and their use as antithrombotic agents F2, F12, VKORC1 ROCK1 1266/4885PLAU 171/4885F12 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.